EYPT · EyePoint, Inc.
$3.19
-0.06 (-1.85%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$312.09M
Shares
86.21M
Volume · Oct 5
2.76M
Avg daily vol (3M)
3.9M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.25
Open$3.31
Day$3.10–3.31
52W close$3.23–18.85
Avg vol 30d3.8M
Short int19.8M · 23.0% float · 6.4d
Short vol60%
Last earningsAug 17, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 22, 2026
Est · unconfirmed
· in 7 wks
filed Aug 5, 2026
call held May 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.79M
Trailing 12 months
Net income (TTM)
−$306.64M
Trailing 12 months
Revenue growth YoY
-90.5%
Year over year
Operating margin
-11,369.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-86.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+23.8%
Year over year · more shares
Price change (1Y)
-75.9%
Trailing year
Short interest
23.0%
Latest settlement · 6.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−74%
below
Price vs 50-day avg
−54%
below
RSI (14)
29
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−29%
trailing
6-month return
−78%
trailing
YTD return
−82%
this year
Relative strength
−90%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $13 — 200d above 50d
Institutional flow
Distributing
1 of 194 funds reported for Sep 30 · net -69 sh shares
Insider flow
Accumulating
Net +$52.3K over 90 days · 0% sells
Short interest
Rising
22.98% of float · ▲ +9.4% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
194 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+365%
Y/Y
EPS growth
−37%
Y/Y
Free cash flow
$-243.4M
Balance sheet
$65.6M
net cash
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
12.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−74%
Bearish
Price vs 50-day avg
−54%
Bearish
RSI (14)
29
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $13 — 200d above 50d
Institutional flow
Distributing
1 of 194 funds reported for Sep 30 · net -69 sh shares
Insider flow
Accumulating
Net +$52.3K over 90 days · 0% sells
Short interest
Rising
22.98% of float · ▲ +9.4% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
194 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 0%
Range high $19
vs 200-day avg -74%
vs 50-day avg -54%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EYPT
this stock
EyePoint, Inc.
|
$312.09M | -82.2% | +664.9% | — | 23.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EYPT | -10.2% | -28.9% | -77.6% | -0.6% | -82.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -10.0% | -28.4% | -89.8% | -1.5% | -95.1% |